Stakeholder Opinions: Hepatocellular cancer - Market Research Report On Aarkstore Enterprise
01/10/2011

Aarkstore.com announce a new report "Stakeholder Opinions: Hepatocellular cancer" through its vast collection of market research report.

Online PR News – 10-January-2011 – – Introduction

Despite the approval of Nexavar (sorafenib; Onyx pharmaceuticals/Bayer), patient outcomes remain poor. The large patient population and the lack of effective agents are driving R&D interest. The majority of pipeline drugs are molecular targeted therapies (MTTs) and their incorporation into treatment will improve both patient outcomes and commercial potential.

Scope of this research

Hepatocellular cancer overview, including disease definition, epidemiology, discussion of unmet needs, and market potential Discussion of current treatment options for Hepatocellular cancer and their limitations Examination of the late-phase hepatocellular cancer pipeline, including drug profiles of late-stage agents Stakeholder opinions based on qualitative interviews with key opinion leaders from the US and Japan Research and analysis highlights
Hepatocellular cancer (HCC) is the fifth and seventh most common cancer in men and women respectively. The majority of patients with HCC are diagnosed with advanced-stage disease and have existing liver damage. The only approved treatment for late-stage disease is Nexavar which is not curative.

Chemotherapy is rarely used in hepatocellular cancer (HCC) as it is associated with low response rates. Regional therapies for early-stage patients have a high exclusion criteria and curative surgery is associated with relapse rates as high as 21.8%. Novel therapies are needed to improve survival rates in both early and late stage disease

There are currently 67 drugs in the pipeline, which is dominated by molecular targeted therapies (71%) and cytotoxic therapies (18%). Competition of late-phase pipeline drugs for first approval in HCC is fierce.

Key reasons to purchase this research

Estimate the number of treatable patients and identify unmet needs for future drug development opportunities Understand the current treatment of the disease, as well as opportunities and threats in the hepatocellular cancer market Analyze the current hepatocellular cancer pipeline and the potential of late-stage drugs

Table of Contents :
Overview 1
Catalyst 1
Summary 1
About Datamonitor healthcare 2
About the Oncology pharmaceutical analysis team 2
About the Epidemiology team 2
Executive Summary 3
Scope of the analysis 3
Datamonitor insight into the hepatocellular cancer market 3
Related reports 4
Upcoming reports 4
Patient Potential 12
Key findings 12
The healthy liver and its function 12
Liver anatomy 12
The function of the liver 13
Liver damage and cirrhosis 13
Hepatocellular cancer 14
Risk factors 15
Hepatitis infection 15
Hepatitis B 15
Hepatitis C 16
Alcohol 17
Aflatoxin exposure 18
Genetic predisposition 18
Diagnosis and screening 19
Complexities of early-stage diagnosis 19
Screening procedures 19
Current diagnosis 20
Staging 20
TNM classification 20
Child-Pugh 20
Cancer of the Liver Italian Program (CLIP) 21
The Barcelona Clinic Liver Classification (BCLC) 21
Treatment options for resectable HCC 22
Liver resection 22
Orthotopic liver transplantation (OLT) 23
Long waiting times due to organ shortage 23
Recurrence 24
Expense 24
Regional therapy; radiofrequency ablation (RFA) 25
Transcatheter arterial chemoembolization (TACE) 26
Percutaneous ethanol injection (PEI) 27
Treatment options for unresectable HCC 28
Chemotherapy: single agents 28
Doxorubicin 30
Cisplatin 31
Gemcitabine 31
Chemotherapy: combination regimens 31
Nexavar (sorafenib; Bayer/Onyx) 32
Nexavar as an adjuvant 36
Unmet need in hepatocellular cancer 37
Increased development of molecular targeted therapies (MTTs) 37
Greater focus on HCC prevention 38
Better designed clinical trials 38
Introduction and background 40
Key points 40
Disease definition and diagnosis criteria 41
Global variation and historical trends in incidence rates 41
Risk factors 46
Environmental risk factors 46
Host risk factors 48
Demographic risk factors 49
Epidemiologic forecasting of hepatocellular cancer 50
Cancer registries: age- and country-specific incidence rates 50
Population denominators 51
Hepatocellular cancer incidence statistical modeling 51
Incidence forecasting 52
Categorization and stratification 53
Age 53
Stage 54
Child-Pugh class 54

For some-more information, Great fully visit:

http://www.aarkstore.com/reports/Stakeholder-Opinions-Hepatocellular-cancer-88054.html